Skip to main content
. 2021 Dec 20;11(12):2401. doi: 10.3390/diagnostics11122401

Table 1.

Features of NET G3 patients.

Variable Level NET G3 p-Value Overall (N = 30)
Upfront (N = 22) Late (N = 8)
Age (y), N (%) <50 7 (32) 2 (25) 1.00 9 (30)
50+ 15 (68) 6 (75) 21 (70)
Median (min–max) 55 (34–70) 56 (44–61) 0.85 56 (34–70)
Sex, N (%) F 7 (32) 6 (75) 0.049 13 (43)
M 15 (68) 2 (25) 17 (57)
Primary site of disease, N (%) Pancreas 13 (59) 7 (88) 0.85 20 (67)
Ileum 3 (14) 0 (0) 3 (10)
Rectum 2 (9) 0 (0) 2 (7)
Stomach 2 (9) 1 (13) 3 (10)
Unknown-primary 2 (9) 0 (0) 2 (7)
Ki-67, N (%) ≤30 10 (45) 6 (75) 0.23 16 (53)
>30 12 (55) 2 (25) 14 (47)
Median (min–max) 33 (21–70) 30 (23–45) 0.34 30 (21–70)
Functioning, N (%) No 18 (82) 7 (88) 1.00 25 (83)
Yes 4 (18) 1 (13) 5 (17)
68Ga-DOTA-TOC PET/CT, N (%) Negative 2 (9) 0 (0) 1.00 2 (7)
Positive and inhomogeneous 4 (18) 1 (13) 5 (17)
Positive and homogeneous 16 (73) 7 (88) 23 (77)
18F-FDG-PET/CT, N (%) Negative 5 (23) 0 (0) 0.47 5 (17)
Positive and inhomogeneous 7 (32) 4 (50) 11 (37)
Positive and homogeneous 10 (45) 4 (50) 14 (47)
Concordance Ga-FDG, N (%) <75% 16 (73) 5 (63) 0.67 21 (70)
≥75% 6 (27) 3 (38) 9 (30)
Prevalence, N (%) 68Ga-DOTA-peptide PET/CT 11 (50) 4 (50) 0.76 15 (50)
18FDG-PET/CT 6 (27) 1 (13) 7 (23)
None 5 (23) 3 (38) 8 (27)
T non-T, N (%) <4 9 (53) 4 (50) 1.00 13 (52)
≥4 8 (47) 4 (50) 12 (48)
Median (min–max) 4.0 (1.8–8.9) 5.4 (1.6–13.0) 0.68 4.0 (1.6–13.0)

1 Among 8 patients with late NET G3, this was the distribution of the years between first diagnosis and G3 diagnosis: Median (min–max): 4.0 (2.3–8.0). 2 For “Late NET G3”, values “after” of 68Ga-DOTA-peptide PET/CT, 18FDG-PET/CT, concordance Ga-FDG, prevalence, and T non-T were considered. 3 For “Late NET G3”, this was the distribution of “before” and “after” values of T non-T: “Before”: Median (min-max): 3.0 (2.4–4.0). “After”: Median (min-max): 5.4 (1.6–13.0).